TJN-259

Antiinflammatory; structure in first source

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

1.	IGA Glomerulonephritis (IGA Nephropathy) 10/01/2009 - "The administration of TJN-259 to mice with spontaneous IgA nephropathy decreased the incidence of mesangial expansion as well as the number of nuclei per glomerular cross-section in comparison with that of non-treated mice. " 10/01/2009 - "With regard to spontaneous IgA nephropathy, we investigated the effects of TJN-259 administered from 28 to 40 weeks. " 10/01/2009 - "TJN-259 improves mesangial lesions in experimental immunoglobulin A nephropathy in ddY mice." 10/01/2009 - "In addition, TJN-259 treatment prevented the increase in the incidence of mesangial expansion, crescent formation, and segmental sclerosis in glomeruli in accelerated IgA nephropathy. " 10/01/2009 - "This study was performed in order to elucidate the antinephritic effects of TJN-259 in experimental immunoglobulin A (IgA) nephropathy. "
2.	Sclerosis 10/01/2009 - "In addition, TJN-259 treatment prevented the increase in the incidence of mesangial expansion, crescent formation, and segmental sclerosis in glomeruli in accelerated IgA nephropathy. "

1.	Immunoglobulin A (IgA)
2.	Transforming Growth Factor beta1 (TGF beta 1)
3.	Collagen Type IV (Type IV Collagen)
4.	Transforming Growth Factors (Transforming Growth Factor)
5.	Proteins (Proteins, Gene)
6.	Immunosorbents
7.	Enzymes
8.	Dihydrotachysterol (AT 10)
9.	Carbon